An Open-Label Study of Azetukalner in Major Depressive Disorder

Study Summary

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).

Conditions

Major Depressive Disorder

Interventions / Drugs

Azetukalner

View on ClinicalTrials.gov ↗

Sponsor

XENE

Xenon Pharmaceuticals

Ion Channel CNS

F34/100

Study Details

Enrollment460 participants

Primary Completion—

Lead SponsorXenon Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:31:52.261426+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.